| Identification | Back Directory | [Name]
Sacubitril Sodium Salt | [CAS]
149690-05-1 | [Synonyms]
Valsartan Sodium
Sacubitril sodium
Sacubitril Sodium Salt
AHU-377 (Sacubitril free base)
sodium 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoate | [Molecular Formula]
C24H28NNaO5 | [MDL Number]
MFCD32004488 | [MOL File]
149690-05-1.mol | [Molecular Weight]
433.473 |
| Chemical Properties | Back Directory | [Melting point ]
163-165°C | [storage temp. ]
-20°C, Hygroscopic | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChIKey]
RRTBVEJIZWGATF-OIRVNKSWNA-M | [SMILES]
[Na+].C([O-])(=O)CCC(N[C@@H](C[C@@H](C)C(OCC)=O)CC1=CC=C(C2=CC=CC=C2)C=C1)=O |&1:8,10,r| |
| Hazard Information | Back Directory | [Description]
Sacubitril Sodium is a potent orally active NEP (enkephalinase) inhibitor with an IC50 of 5 nM. Sacubitril Sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril Sodium is a component of the heart failure drug LCZ696. Sacubitril Sodium is used in heart failure, hypertension and COVID-19 studies. | [Uses]
Sacubitril Sodium Salt is a salt of Sacubitril, an antihypertensive drug used in combination with valsartan. The combination drug, valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name, Entresto, is a treatment for heart failure. | [in vivo]
In normotensive rats, pretreatment with Sacubitril sodium (3, 10 and 30 mg/kg, PO.) augments ANP-evoked plasma cGMP levels by 2.4, 3.3 and 4.0 fold, respectively (4h AUC compared to vehicle)[1].
Sacubitril sodium (30 and 100 mg/kg, PO) produces a dose-dependent antihypertensive effect in Dahl-SS rats[1]. |
|
|